Skip to main content
OpenTrials
Completed

NCT Number: NCT01356407

Investigation of PICOPREP and PEG-ELS for Bowel Preparation for Colonoscopy

Eligible subjects undergoing a colonoscopy will randomly receive either PICOPREP or polyethylene glycol 4000 electrolyte lavage solution before the procedure to evaluate its effectiveness, tolerability and safety.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Colonoscopy

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Nanfang Hospital, Southern Medical University, Guangzhou, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have signed the informed consent form and have been verbally explained the details of the trial and treatment procedures
  • Chinese citizen
  • Males or females aged between 18 and 70 years inclusive
  • Patients scheduled for colonoscopy
  • Patients who are able to observe instructions given during the study, and are able to complete the entire study procedure

Exclusion criteria

  • Those pregnant, breastfeeding, or with the intention of becoming pregnant, or fertile women who are not on effective birth control
  • Taking concomitant lithium
  • Allergy to any ingredient in the study medication
  • History of gastrointestinal diseases (active ulcers, gastric outlet obstruction, gastric retention, intestinal obstruction)
  • Colon diseases (toxic megacolon, toxic colitis, idiopathic intestinal pseudo-obstruction, gastric retention, intestinal obstruction, lazy bowel syndrome) at screening
  • Active (acute/severe/uncontrolled) Inflammatory Bowel Disease (IBD)
  • Acute abdominal symptoms (acute intestinal obstruction, intestinal perforation, diverticulitis or appendicitis)
  • Ascites
  • History of surgery in upper gastrointestinal tract (gastrectomy, gastric banding, gastric bypass surgery)
  • History of colorectal surgery (excluding appendectomy, hemorrhoidectomy and endoscopic surgery)
  • Uncontrolled angina and/or myocardial infarction, congestive heart failure, or uncontrolled hypertension within 3 months prior randomisation
  • Severe liver damage
  • Kidney function impairment
  • Diabetics currently on insulin treatment
  • Having participated in any other clinical trial during the 3 month prior recruitment
  • Patients who are unable to act in a legal capacity, unable to meet or perform study requirements

Treatment and study plan

PICOPREP

Drug

PEG-ELS

Drug

Primary outcomes

  1. The Ottawa Scale Score of Patients Who Had Successfully Completed the Colonoscopy Examination After Having Completed the Study Bowel Preparation

    Time frame: day 2

    The total Ottawa Bowel Preparation Scale (OBPS) score, rated by the treatment-blinded Investigator at colonoscopy, was designed to evaluate cleanliness of the colon by grading the endoscopic visibility of the mucosa according to a scale from 0 ('excellent' visibility) to 4 ('inadequate' visibility); The component scores for each of the colon segment are added together, along with an overall 'fluid' score (from small amount = 0, to large amount = 2). Thus, the total OBPS has a range from 0 (a perfect preparation) to 14 (a completely unprepared bowel)

Secondary outcomes

  1. Patient Response to Acceptability and Tolerability Questionnaire

    Time frame: Day 2

    On the day of the procedure, but before colonoscopy or any sedation for colonoscopy, subjects were asked to complete a standardised questionnaire regarding whether or not complete the IMP (yes or no), ease of taking IMP (rating from 1 point(very easy) to 5 point (very difficult)), degree of acceptability to study med (rating from 1 point (excellent) to 5 point (bad)), palatability of IMP (rating from 1 point (excellent) to 5 point (bad)) and tolerability (5 adverse reactions including abdominal bloating, spasms, nausea, vomiting and general malaise which were generally reported in bowel preparation with rating according to intensity from 1 point (None) to 4 point (Severe)).

  2. Ottawa Scale Score by Colon Segment

    Time frame: Day 2

    Mean Ottawa Scale scores, and score categories (from 'excellent' to 'bad'), are summarised by colon segment together with the overall fluid content score

  3. Percentage of Successful Completion of Colonoscopy

    Time frame: Day 2

    An overview of completion rates of colonoscopy (i.e., endoscope reaching the ileocecal valve)

  4. Proportion of Successful Colonoscopies in the Clinical Setting (Predicted by Ottawa Scale Score)

    Time frame: Day 2

    At colonoscopy, bowel preparations were rated by the treatment-blinded endoscopist, as being of an overall quality "adequate for clinical diagnostic purposes" (Y/N). The total Ottawa Scale scores was correlated with 'adequate' or 'inadequate' quality of bowel preparation for clinical diagnostic purposes

  5. Proportion of Subjects Requiring a Repeat Colonoscopy Due to Poor Bowel Preparation

    Time frame: Day 2

    The Proportion of subjects requiring a repeat colonoscopy due to poor bowel preparation

Sponsors and collaborators

Lead sponsor

Ferring Pharmaceuticals

Industry

Registry information

Official study title

A Multi-center, Randomized, Single-blind Clinical Study of the Efficacy and Safety of PICOPREP and Polyethylene Glycol-electrolyte 4000 Powder for Oral Solution (PEG-ELS) for the Bowel Preparation Prior Colonoscopy

Important dates

Study start
2011
Primary completion
2011
Study completion
2011
First posted
May 19, 2011
Registry last updated
Jan 28, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.